



University of the
West of England

BRISTOL

Forshaw, T. E. (2017) *The role of increased hBCATm in the endothelial cells of patients with Alzheimers disease*. PhD, University of the West of England. Available from: <http://eprints.uwe.ac.uk/29844>

We recommend you cite the published version.

The publisher's URL is:

<http://eprints.uwe.ac.uk/29844/>

Refereed: No

(no note)

Disclaimer

UWE has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material.

UWE makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.

UWE makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights.

UWE accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement.

PLEASE SCROLL DOWN FOR TEXT.



The role of increase hBCAT^m in the endothelial cells of patients with Alzheimer's Disease.

Thomas Edward Forshaw

Department of Biological, Biomedical and Analytical Sciences,

University of the West of England, Bristol.

September 2016

A thesis submitted in partial fulfilment of the requirements of the University of the West of England, Bristol for the degree of Doctor of Philosophy.

This work was partly funded by BRACE

(Bristol Research into Alzheimer's and Care of the Elderly).

Copyright disclaimer

This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.

ACKNOWLEDGEMENTS.

This thesis, and the research contained within, could not have been achieved without my friends, family, colleagues, and supervisory team. I would like to take a moment to thank them all for everything they have done for me.

Firstly, I would like to thank my director of studies, Prof. Myra Conway, for her continued support, enthusiasm, and belief in me. I have learnt such an incredible amount over the past four years, and it was only possible through Myra's teachings and hard work. A childhood dream has literally come true.

I must also thank my second supervisors, Dr. Annabelle Hodson for her expert advice in chemistry, and Dr. Carolyn Paul for her expertise in the blood-brain barrier and contribution to the building of a cell culture model. Again, their hard work has made this possible.

Academically I would like to thank Dr. Craig Butts at the University of Bristol for use and training in NMR spectroscopy, Dr. James Costello for advice on drug design and chemical synthesis, Dr. Man-Kim Cheung for his guidance on molecular biology, and Dr. Anneke Lubben at the University of Bath for providing LC-MS analysis of compounds. Thank you to Team Conway, past and present - Chris, Matt, Jon, Maya, Mo, Marcela, Anna, Grace, Fred, and Mai. I had the pleasure of working with four undergraduate students in my third year and tutoring them on laboratory techniques. They also helped provide data for this thesis and I would like to thank Bethany Samways, Elsa Aguiar, Jovi Workman, and Matt Heyda. I would also like to thank the technical team at both UWE and UoB.

Finally (but very importantly), my friends and family. Karen, Alan, Michael, Siân Parry (incredible patience), James Billett, Morgan Lewis, Max Hughes, Jason Redican (stealer of socks), Abbey May, Jon Quirk, Niamh Ní Branghaile, Gareth Hughes, Liz Bowler, Simon Andrews, Mike Devey, Strong Coffee, Mars Skittles, Thatchers Cider, The Ratties, and all who have been there with me on my journey.

Dedicated to the memory of Thomas William Joynes.

Rest in peace, granddad.

ABSTRACT.

Introduction and aims: The branched-chain aminotransferase (BCAT) enzymes are important in the regulation of brain L-glutamate. A unique function of these aminotransferases is their regulation by the redox environment, where our group have shown their function as oxidoreductases, and their ability to refold misfolded proteins in particular when S-glutathionylated. Our group recently showed a significant increase in the level of these proteins in Alzheimer's disease brain. An increase in BCAT activity could generate excess L-glutamate, contributing to the excitotoxic environment observed under pathogenic conditions. Alternatively, we hypothesize that if this protein is modified in response to cellular stress, it may play a more prominent role in regulating redox status or protein folding. To address these questions this project focussed on the design of chemical inhibitors and knock-down models together with a co-culture model of the human cerebrovasculature and specifically targeted key metabolic and redox pathways.

Methods: Several chemical inhibitors based on 4-Benzoyloxyphenylacetic acid were identified using the DockBlaster and Schrödinger software suites, synthesized and structurally verified using proton nuclear magnetic resonance (NMR) spectroscopy. The functional impact and specificity of these inhibitors was assessed using the BCAT radiolabelled assay and a coupled-enzyme assay. In tandem, siRNA was used to knock-down both isoforms in SH-SY5Y cells, and validated using western blot analysis and RT-PCR. The impact of BCATm knock-down on the expression of redox proteins, in addition to selected metabolic proteins, was assessed by western blot analysis. Functional redox assays, including glutathione concentration and metabolic activity, were also used to investigate the impact of human BCAT (hBCAT) expression in neuronal cells. Finally, a model of the blood-brain barrier (BBB) was developed and validated for studies into the role of mitochondrial hBCAT (hBCATm) in brain microvasculature.

Results: For the first time we have identified a family of chemical inhibitors of hBCATm. In particular, benzofenac has a two-fold greater enzyme affinity for hBCATm ($K_i=43 \mu\text{M}$) than cytosolic hBCAT (hBCATc) ($K_i=93 \mu\text{M}$) and a four-fold greater inhibition relative to alanine transaminase (ALT; $K_i=167 \mu\text{M}$). These inhibitors will require further optimisation but have potential as tools to assess the cellular function of hBCAT. In separate studies, knock-down of hBCATm in SH-SY5Y neuronal cells demonstrated that hBCATm expression has an impact on the metabolic and redox status of the cell. In particular, knock-down caused a >70% decrease in glutaredoxin (GRx), thioredoxin (TRx), branched-chain α -keto acid dehydrogenase α -subunit (BCKDHA), and AU-rich binding homolog of enoyl-CoA hydratase (AUH) expression. Interestingly, this effect was attenuated when cells were treated with L-leucine, indicating that these mechanisms may be regulated by a metabolic signal. L-glutamate treatment was also found to significantly increase hBCATm expression, but decreased glutamate dehydrogenase (GDH) expression, except in cells overexpressing hBCATm, suggesting a metabolic synergy between the two enzymes. Finally, total glutathione concentration was significantly decreased on hBCATm knock-down, while sensitivity to L-glutamate toxicity was significantly increased.

Discussion: Results from this work have significantly contributed to the design of cellular models, which can be used to further investigate the role of BCAT in metabolic and redox metabolism. A model of the human blood-brain barrier, developed in this thesis, will also contribute to evaluating the endothelial role of hBCATm. The initial impact of limiting BCAT expression is both a decrease in the expression of key metabolic proteins and also the cellular reductants. Together this had an impact on cell survival. Knowledge of these pathways and their regulation will be important to our understanding, of not only the regulation of brain L-glutamate, but also the role of BCAT in protein folding and cellular redox status. These factors are fundamentally important to development of neurodegenerative conditions but also in tumour development such as gliomas.

ABBREVIATIONS.

3MeBOPAA – 3-methyl-4-[(4-methylbenzyl)oxy]-phenylacetic acid

3OMeBOPAA – 4-(benzyloxy)-3-hydroxy-phenylacetic acid

4EBP1 – Eukaryotic translation initiation factor 4E-binding protein 1

AAOA – Aminoxyacetic acid

A β – Amyloid β peptide

A β 40 – Amyloid β peptide 1-40

A β 42 – Amyloid β peptide 1-42

AD – Alzheimer's disease

AJ – Adherens junctions

Akt – RAC-alpha serine/threonine-protein kinase

ALT – Alanine transaminase

AMPA – α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

AMPK – 5' adenosine monophosphate-activated protein kinase

APP – Amyloid precursor protein

APS – Ammonium persulphate

ARE – Antioxidant-response element

AST – Aspartate aminotransferase

ATF4 – Activating transcription factor 4

ATP – Adenosine triphosphate

AUH – AU RNA binding protein/enoyl-CoA hydratase

BBB – Blood brain barrier

BCAA – Branched-chain amino acids

BCAT – Branched-chain aminotransferase

BCAT1 – Branched-chain aminotransferase gene (cytosolic isoform)

BCAT2 – Branched-chain aminotransferase gene (mitochondrial isoform)

BCKA – Branched-chain α -keto acid

BCKD – Branched-chain α -keto acid dehydrogenase

BCKDHA – Branched-chain α -keto acid dehydrogenase, E1 α subunit

BiP – Binding immunoglobulin protein

Benzofenac – 4-(benzyloxy)-3-chloro-phenylacetic acid

BOPAA – 4-(benzyloxy)phenylacetic acid

BSA – Bovine serum albumin

CHOP – C/EBP [CCAAT/enhancer binding protein] homologous protein

cDNA – Complementary DNA

CSF – Cerebrospinal fluid

Cys – Cysteine

DCC – N,N-dicyclohexylcarbodiimide

DCM – Dichloromethane

ddDNA – Double stranded DNA

DMAP – 4-dimethylaminopyridine

DMEM – Dulbecco's Modified Eagle's medium

DMF – Dimethylformamide

DPM – Disintegrations per minute

DTNB – 5,5'-dithiobis-2-nitrobenzoic acid

DTT – Dithiothreitol

E-PLP – Enzyme-Pyridoxal L-phosphate complex

E-PMP – Enzyme-Pyridoxal monophosphate complex

FBS – Fetal bovine serum

EAAT1 – Excitatory amino acid transporter 1

EDTA – Ethylenediaminetetraacetic acid

eGFP – Enhanced green fluorescent protein

EGTA – Ethyleneglycoltetraacetic acid

eIF2 α – Eukaryotic translation initiation factor 2 α

FT-IR – Fourier transform infrared

GABA – γ -aminobutyric acid

GAD – L-glutamate decarboxylase

GAPDH – Glyceraldehyde 3-phosphate dehydrogenase

GC – Gas chromatography

GC-MS – Gas chromatography coupled mass spectrometry

GDH – Glutamate dehydrogenase

GLUT1 – Glucose transporter 1

GPx – Glutathione peroxidase

GRx – Glutaredoxin

GS – Glutamine synthase

GSH – Glutathione (reduced)

GSK3 β – Glycogen synthase kinase 3 β

GSSG – Glutathione (oxidized)

HAPAA – 2-hydroxy-4-(4-methylbenzoyl)aminophenylacetic acid

hBCAT – Human branched-chain aminotransferase

hBCATc – Human branched chain aminotransferase (cytosolic isoform)

hBCATm – Human branched-chain aminotransferase (mitochondrial isoform)

HBSS – Hank's buffered salt solution

HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HMG-CoA - 3-hydroxy-3-methylglutaryl-coenzyme A

HSPAA – 2-hydroxy-4-[[4-methylphenyl)sulfanyl]carbonyl]phenylacetic acid

HTS – High-throughput screening

IC50 – Half maximal inhibitory concentration

IPTG – Isopropyl β -D-1-thiogalactopyranoside

IRS – Insulin receptor substrate

ISR – Integrated stress response

KA – Kainic acid

K_{cat} – Substrate molecules turned over per enzyme molecule, per second

KEAP1 – Kelch-like ECH [erythroid cell-derived protein with CNC homology]-associated protein 1

K_{eq} – Equilibrium constant

KG – α -Ketoglutarate

KIC – α -ketoisocaproate

KIV – α -ketoisovalerate

Klf15 – Kruppel-Like Factor 15

KMV – α -keto- β -methylvalerate

KMV - Keto- β -methylvalerate

LC-MS – Liquid chromatography coupled mass spectrometry

LDS – Lithium dodecyl sulphate

LNAAT – Large neutral amino acid transporter

MAP – Microtubule-associated protein

MAPT – Tau microtubule-associated protein gene

Mct – Monocarboxylic acid transporter

MeBenzofenac – 3-chloro-4-[(4-methylbenzyl)oxy]-phenylacetic acid

MG-CoA – 3-methylglutaconyl-CoA

MOPS – 3-(N-morpholino)propanesulfonic acid

MS – Mass spectrometry

MSUD – Maple syrup urine disease

mTOR – Mammalian target of Rapamycin

mTOR1 – Mammalian target of Rapamycin complex 1

MTS – 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium

NADH – Nicotinamide adenine dinucleotide

NADPH – Nicotinamide adenine dinucleotide phosphate

Na-Flu – Sodium fluorescein

NEM – N-ethylmaleimide

NFT – Neurofibrillary tangles

NMDA – N-methyl-D-aspartic acid

NMDAR – N-methyl-D-aspartic acid receptor

NMR – Nuclear magnetic resonance (spectroscopy)

NO – Nitric oxide

Nrf2 – Nuclear factor (erythroid-derived 2)-like 2

P70S6K – Ribosomal protein S6 kinase beta-1

p-eIF2 α – Phosphorylated eukaryotic translation initiation factor 2 α

P-gp – P-glycoprotein

PAG – Phosphate- activated glutaminase

PDI – Protein disulphide isomerase

Pe – Permeability coefficient

PERK – Protein kinase RNA-like endoplasmic reticulum kinase

PI3K – Phosphoinositide 3-kinase

pIC50 – negative logarithm of IC50 [Half maximal inhibitory concentration]

PLP – Pyridoxal L-phosphate

PMP – Pyridoxine monophosphate

PP18b – Placental protein 18b

PP2A – Protein phosphatase 2A

Rheb – Ras homolog enriched in brain

RNAi – RNA interference

ROS – Reactive oxygen species

RT – Retention time

SDS – Sodium dodecyl sulphate

shRNA – Short hairpin RNA

siRNA – Small interfering RNA

ssRNA – Single stranded RNA

SOD – Superoxide dismutase

TBS – Tris-buffered saline

TBST – Tris-buffered saline with Tween-20

TCA – Trichloroacetic acid

TEMED – Tetramethylethylenediamine

Tris – Hydroxymethylaminomethane

TJ – Tight junction

TOR – Target of Rapamycin

TR – Thyroid receptor

TRx – Thioredoxin

TSC1 – Tuberous sclerosis 1

U – Enzyme units

VDCC – Voltage dependent calcium channels

ZO – Zonula occludens

PRESENTATIONS AND PUBLISHED WORKS.

Oral presentation

“BCAT and the brain” Postgraduate research forum 2015, University of the West of England.

Poster presentations

“The importance of the AAA: Alzheimer’s, autophagy and aminotransferases” Alzheimer’s research UK 2015, University College London.

“Synthesis and testing of a selective hBCATm chemical inhibitor” CRIB forum 2015, University of the West of England.

“The design of enzyme inhibitors to aid investigation into the role of branched-chain aminotransferase in neurological disease” CRIB forum 2014. University of the West of England.

Publications

El Hindy, M., Hezwani, M., Corry, D., Hull, J., El Amraoui, F., Harris, M., Lee, C., **Forshaw, T.**, Wilson, A., Mansbridge, A., Hassler, M., Patel, V. B., Kehoe, P. G., Love, S., Conway, M. E. (2014) The branched-chain aminotransferase proteins: novel redox chaperones for protein disulfide isomerase--implications in Alzheimer's disease. Antioxid. Redox. Signal. 20(16): 2497-2513

Forshaw, T. E. & Conway M. E. Differential regulation of the hBCAT proteins by S-Nitrosation and S- Glutathionylation. (Submitted - awaiting publication)

CONTENTS.

ACKNOWLEDGEMENTS.	iii
ABSTRACT.	iv
ABBREVIATIONS.	v
PRESENTATIONS AND PUBLISHED WORKS.	xi
CONTENTS.	xii
FIGURE CONTENTS.	xviii
TABLE CONTENTS.	xxiv

CHAPTER ONE – INTRODUCTION AND MAIN AIMS.

1.1 – Branched chain aminotransferase.	2
1.2 – hBCAT enzyme kinetics.	4
1.3 – The structure of the hBCAT proteins.	6
1.4 – Human branched-chain amino acid metabolism.	10
1.5 – Redox regulation of hBCAT and relation to other redox proteins.	15
1.6 – hBCAT distribution.	19
1.7 – BCAT and the glutamate-glutamine cycle.	21
1.8 – hBCAT and the BCAAs in the brain.	25
1.8.1 – Maple syrup urine disease.....	25
1.8.2 – Excitotoxicity pathway.	27
1.9 – Alzheimer’s disease.	31
1.9.1 – Amyloid pathology.	32
1.9.2 – Tau pathology.....	33
1.9.3 – Protein synthesis and autophagy.....	35
1.9.4 – Protein misfolding and redox pathology.	37
1.9.5 – The blood-brain barrier.	38
1.10 – Aims and objectives.	45

CHAPTER TWO – MATERIALS AND METHODS.

2.1 – MATERIALS.....	48
2.1.1 – Equipment.....	54
2.1.2 – Software.....	54
2.1.3 – Plasmids.....	54
2.1.4 – Primers.....	55
2.1.5 – Antibodies.....	56
2.1.6 – Cell lines.....	57
2.2 – METHODS.....	57
2.2.1 – Purification of hBCAT proteins.....	57
2.2.2 – Protein estimation using the Bradford assay.....	59
2.2.3 – SDS-PAGE gel electrophoresis.....	59
2.2.4 – Estimation of reaction thiols using the 5,5'-dithiobis-2-nitrobenzoic acid assay.....	60
2.2.5 – Validation of synthesised chemical structure using spectroscopy.....	60
2.2.6 – Gabapentin synthesis.....	61
2.2.7 – Computer simulation of structure based ligand discovery.....	63
2.2.8 – Trial synthesis of 3-[(chloroacetyl)oxy]benzoic acid.....	64
2.2.9 – Trial synthesis of amide based hBCATm inhibitor.....	64
2.2.10 – Ester intermediate used for synthesis of phenylacetic acid derived hBCATm inhibitors.....	66
2.2.11 – Morpholide intermediate used for synthesis of benzyloxyphenylacetic acid derived hBCATm inhibitors.....	67
2.2.12 – Radioactive substrate BCAT activity assay.....	68
2.2.13 – BCAT coupled enzyme assay.....	71
2.2.14 – ALT activity assay.....	71
2.2.15 – Synthesis of siRNA.....	72
2.2.16 – Mammalian cell culture.....	75
2.2.17 – Transient cell transfections of expression plasmids and siRNA.....	76
2.2.18 – Spin-column purification of RNA from cultured cells.....	77

2.2.19 – cDNA synthesis from isolated RNA.	79
2.2.20 – Analysis of gene expression by RT-PCR.	79
2.2.21 – Agarose gel electrophoresis.	79
2.2.22 – Extraction of mammalian cell lysate.	80
2.2.23 – Protein estimate using amido black method.	80
2.2.24 – Wet protein transfer and western blot analysis of cell lysate.	81
2.2.25 – Estimate of cell viability and metabolic activity by MTS reduction assay.	82
2.2.26 – Cellular glutathione concentration assay using DTNB.	82
2.2.27 – Determining permeability of hCMEC/D3 monolayers.	84
2.2.28 – Transforming of plasmids into Stellar competent cells.	86
2.2.29 – Plasmid preparation.	86
2.2.30 – Cloning of BCAT2 gene into pCW57.1 plasmid.	86
2.2.31 – Synthesis of tet-pLKO-puro-BCAT2 shRNA plasmid.	87
2.2.32 – Statistical analysis.	88

CHAPTER THREE – CHEMICAL SYNTHESIS AND ANALYSIS OF A SELECTIVE HBCATM INHIBITOR.

3.1 – INTRODUCTION.	91
3.2 – SPECIFIC AIMS.	96
3.3 – RESULTS.	97
3.3.1 – Overexpression and purification of hBCAT enzymes.	97
3.3.2 – Characterisation of hBCAT enzymes.	97
3.3.3 – Synthesis of Gabapentin.	104
3.3.4 – Effect of lead compounds on hBCAT transamination.	107
3.3.5 – Computer aided development of an hBCATm specific inhibitor.	115
3.3.6 – Synthesis of HSPAA chemical inhibitor.	119
3.3.7 – Synthesis of HAPAA chemical inhibitor.	124
3.3.8 – Synthesis of BOPAA derivative inhibitors.	148
3.3.9 – Biological testing of novel hBCATm inhibitor compounds.	166

3.3.9.1 – Effect of BOPAA family compounds on hBCAT transamination.....	170
3.3.9.2 – Metabolic effect of benzofenac on neuronal cells.	177
3.4 – DISCUSSION.	182
3.4.1 – Design of a selective hBCATm inhibitor.....	182
3.4.2 – Synthesis of a selective hBCAT inhibitor.	185
3.4.2.1 – Synthesis of the BOPAA family compounds.....	187
3.4.3 – Testing of hBCAT inhibitors.	191
3.4.3.1 – The effect of anti-epileptic drugs on hBCAT transamination activity.	191
3.4.3.2 – Impact of BOPAA family compounds on hBCAT transamination.	195
3.4.4 – Effect of benzofenac on SH-SY5Y cell viability.	198
3.4.5 – Summary.....	199

THE ROLE OF HBCATM IN REDOX STATUS AND METABOLISM.

4.1 – INTRODUCTION.	204
4.2 – SPECIFIC AIMS.	209
4.3 – RESULTS.	210
4.3.1 – Development of hBCAT siRNA.....	210
4.3.2 – qPCR validation of siRNA.....	210
4.3.3 – Western blot analysis of redox chaperone and metabolic proteins in modified hBCATm expression systems.	215
4.3.3.1 – Western blot analysis of hBCATm in L-leucine treated SH-SY5Y cells.	219
4.3.3.2 – Western blot analysis of PDI in L-leucine treated SH-SY5Y cells.	219
4.3.3.3 – Western blot analysis of GRx-1 in L-leucine treated SH-SY5Y cells.	221
4.3.3.4 – Western blot analysis of TRx-1 in L-leucine treated SH-SY5Y cells.	223
4.3.3.5 – Western blot analysis of BCKDHA in L-leucine treated SH-SY5Y cells.	223
4.3.3.6 - Western blot analysis of AUH in L-leucine treated SH-SY5Y cells.	226
4.3.3.7 - Western blot analysis of hBCATm in L-glutamate treated SH-SY5Y cells.	226

4.3.3.8 - Western blot analysis of GDH in L-glutamate treated SH-SY5Y cells...	229
4.3.4 - Measuring intracellular glutathione.....	229
4.3.4.1 - Determination of total cellular glutathione concentration.....	232
4.3.4.2 - Determination of oxidised cellular glutathione concentration.....	232
4.3.4.3 - Determination of reduced cellular glutathione concentration.....	238
4.3.4.4 - GSH:GSSG ratio in hBCATm transfected and oxidised SH-SY5Y cells.	238
4.3.5 - Cell viability of transfected and L-glutamate treated cells by MTS assay. ...	241
4.4 – DISCUSSION.	243
4.4.1 – Impact on redox chaperones and glutathione concentration.....	246
4.4.2 – The impact of L-leucine on SH-SY5Y cells.	250
4.4.3 – The impact of L-glutamate on SH-SY5Y cells.....	255
4.4.4 – Summary.....	259

IN VITRO MODELLING OF THE HUMAN BLOOD-BRAIN BARRIER.

5.1 – INTRODUCTION.	261
5.2 – SPECIFIC AIMS.	266
5.3 – RESULTS.....	267
5.3.1 – Monolayer integrity evaluation using TEER.	267
5.3.2 – Monolayer integrity evaluation using Na-Flu.	267
5.3.3 - Expression of tight junction proteins in hCMEC/D3 cells.	268
5.3.4 - Transfection of hCMEC/D3 cells.....	270
5.3.5 - Design and synthesis of hBCAT lentiviral plasmids.	278
5.3.5.1 - Synthesis of hBCAT shRNA plasmids.....	280
5.4 – DISCUSSION.	285
5.4.1 – Validation of hCMEC/D3 monolayers as a representation of the BBB.	285
5.4.2 – Transfection of the hCMEC/D3 cell line.	286
5.4.3 – Development of lentiviral vectors for stable inducible transfection.	287

5.4.4 – Summary..... 289

CHAPTER SIX – SYNOPSIS, CONCLUSION, AND FUTURE WORK.

6.0 – SYNOPSIS AND CONCLUSION..... 291

6.1 – FUTURE WORK..... 298

REFERENCES..... 300

APPENDIX..... 349

FIGURE CONTENTS.**CHAPTER ONE – INTRODUCTION AND MAIN AIMS.**

<i>Figure 1.1</i> – Ping-pong kinetics of the BCAT enzymes.....	5
<i>Figure 1.2</i> – Structure of hBCATm protein.....	8
<i>Figure 1.3</i> – Metabolism of the branched-chain amino acids.....	11
<i>Figure 1.4</i> – hBCATm-BCKD-GDH metabolon.	13
<i>Figure 1.5</i> – Oxidation of the CXXC motif in hBCAT.	17
<i>Figure 1.6</i> – The rat model of the glutamate-glutamine cycle.....	23
<i>Figure 1.7</i> – The human glutamate-glutamine cycle.....	24
<i>Figure 1.8</i> – The glutamate-mediated excitotoxic pathway.....	29
<i>Figure 1.9</i> – mTOR1 pathway.....	36
<i>Figure 1.10</i> – Mechanisms of the BBB.	41
<i>Figure 1.11</i> – The vascular two-hit hypothesis of AD.....	43

CHAPTER TWO – MATERIALS AND METHODS.

<i>Figure 2.1</i> – The components of the hBCAT kinetic assay.	69
<i>Figure 2.2</i> – Design of DNA templates for siRNAs to silence a target gene.	74

CHAPTER THREE – CHEMICAL SYNTHESIS AND ANALYSIS OF A SELECTIVE HBCATM INHIBITOR.

<i>Figure 3.1</i> – Binding of gabapentin to hBCAT... ..	92
<i>Figure 3.2</i> – The structures of the branched chain amino acids and valproic acid.	93
<i>Figure 3.3</i> – Purification of hBCATc and mutant proteins.	99
<i>Figure 3.4</i> – Purification of hBCATm and mutant proteins.....	100
<i>Figure 3.5</i> – The protein content of a sample of purified hBCATm.	101

Figure 3.6 – The DTNB accessible free thiol groups of hBCATc and respective mutants.	102
Figure 3.7 – The DTNB accessible thiol groups of hBCATm and respective mutants.	103
Figure 3.8 – The synthesis of gabapentin from 1,1-cyclohexanediactic acid via the Hoffman rearrangement.	106
Figure 3.9 – Gas chromatogram of synthesised gabapentin.	108
Figure 3.10 – Mass spectrum of synthesised gabapentin.	109
Figure 3.11 – Mass spectrum of gabapentin lactam obtained from the NIST database.	110
Figure 3.12 – The effect of valproic acid on hBCAT activity.	113
Figure 3.13 – Chemical structure of a potential lead hBCATm ligand.	116
Figure 3.14 – The progression of lead development for an hBCATm inhibitor ..	118
Figure 3.15 – The binding of HSPAA to residues of hBCATm.	120
Figure 3.16 – The binding of HSPAA to residues of hBCATc.	121
Figure 3.17 – The binding of HSPAA in the substrate pocket of hBCATm.	122
Figure 3.18 – Synthesis pathway to HSPAA.	123
Figure 3.19 – Synthesis pathway of HAPAA inhibitor compound.	125
Figure 3.20 – Aromatic Claisen rearrangement.	127
Figure 3.21 – FT-IR spectra of 3-aminophenol starting material.	128
Figure 3.22 – FT-IR spectra of amide compound.	129
Figure 3.23 – Gas chromatogram of product from first step in HAPAA synthesis.	130
Figure 3.24 – Mass spectrum of product from first step in HAPAA synthesis. ...	131
Figure 3.25 – FT-IR spectra of allyl ether compound.	132
Figure 3.26 – Gas chromatogram of product from second step in HAPAA synthesis.	133
Figure 3.27 – Mass spectrum of allyl ether product.	134
Figure 3.28 – Mass spectrum of proposed cyclic derivative.	135
Figure 3.29 – UV-Vis spectrum of the allyl ether compound before Claisen rearrangement.	137

<i>Figure 3.30</i> – UV-Vis spectrum of the allyl ether compound during and after the Claisen rearrangement reaction.	138
<i>Figure 3.31</i> – FT-IR spectra of rearranged alkene compound.	139
<i>Figure 3.32</i> – Liquid chromatography analysis of Claisen rearrangement product.	140
<i>Figure 3.33</i> – Positive ion mass spectrum of Claisen rearrangement product. .	141
<i>Figure 3.34</i> – FT-IR spectra of failed OsO ₄ oxidation product.	143
<i>Figure 3.35</i> – Gas chromatogram of failed OsO ₄ oxidation product.	144
<i>Figure 3.36</i> – Mass spectrum of unreacted allyl phenol starting material from oxidation reaction.	145
<i>Figure 3.37</i> – Mass spectrum of cyclic rearrangement impurity from oxidation reaction.	146
<i>Figure 3.38</i> – Mass spectrum of allyl phenol isomer as unreacted starting material from oxidation reaction.	147
<i>Figure 3.39</i> – The six phenylacetic acid derivative compounds synthesised. ...	149
<i>Figure 3.40</i> – Protected carboxylic acid synthesis route for phenylacetic acid derivative inhibitors.	150
<i>Figure 3.41</i> – Modified Willgerodt-Kindler rearrangement synthesis route for phenylacetic acid derivative compound (inhibitor 5).	151
<i>Figure 3.42</i> – FT-IR spectra of phenylacetic acid starting material.	152
<i>Figure 3.43</i> – FT-IR spectra of protected carboxylic acid.	153
<i>Figure 3.44</i> – Gas chromatogram of first step in benzofenac synthesis.	155
<i>Figure 3.45</i> – Mass spectrum of methyl 3-chloro-4-hydroxyphenylacetate.	156
<i>Figure 3.46</i> – FT-IR spectra of protected carboxylic acid.	157
<i>Figure 3.47</i> – Gas chromatogram of ether coupling for second step in benzofenac synthesis.	158
<i>Figure 3.48</i> – Mass spectrum of second step in benzofenac synthesis.	159
<i>Figure 3.49</i> – FT-IR spectra of benzofenac.	160
<i>Figure 3.50</i> – NMR spectrum of BOPAA.	152
<i>Figure 3.51</i> – NMR spectrum of 3OMeBOPAA.	163
<i>Figure 3.52</i> – NMR spectrum of benzofenac.	164

<i>Figure 3.53</i> – NMR spectrum of Me-benzofenac.....	165
<i>Figure 3.54</i> – Gas chromatogram of ether coupling before Willgerodt-Kindler rearrangement.....	167
<i>Figure 3.55</i> – Mass spectrum of ether coupling before Willgerodt-Kindler rearrangement.....	168
<i>Figure 3.56</i> – NMR spectrum of 3MeBOPAA.....	169
<i>Figure 3.57</i> – HPAAs inhibition kinetics for hBCATm.....	171
<i>Figure 3.58</i> – HPAAs inhibition kinetics for hBCATc.....	172
<i>Figure 3.59</i> – Inhibition of hBCAT by the five synthesised inhibitors.....	173
<i>Figure 3.60</i> – Benzofenac inhibition kinetics for hBCATm.....	175
<i>Figure 3.61</i> – Benzofenac inhibition kinetics for hBCATc.....	176
<i>Figure 3.62</i> – Michaelis-Menten kinetics of ALT.....	178
<i>Figure 3.63</i> – Benzofenac inhibition kinetics of ALT.....	179
<i>Figure 3.64</i> – Metabolic impact of benzofenac on SH-SY5Y neuronal cells.....	181
<i>Figure 3.65</i> – Potential improvements to synthesis of HAPAA.....	186
<i>Figure 3.66</i> – Similarities between recently published BCATm inhibitor fragments and the BOPAA family compounds.....	190
<i>Figure 3.67</i> – GSK-3 β and BCAT in mTOR signalling.....	194
<i>Figure 3.68</i> – Suggested future BOPAA family compounds for inhibitor development.....	197

CHAPTER FOUR – THE ROLE OF HBCATM IN REDOX STATUS AND METABOLISM.

<i>Figure 4.1</i> – The cellular anti-stress pathways pathway.....	205
<i>Figure 4.2</i> – siRNA sequences selected from BCAT1 transcript variant 1 cDNA sequence.....	211
<i>Figure 4.3</i> – siRNA sequences selected from BCAT2 transcript variant a cDNA sequence.....	212
<i>Figure 4.4</i> – Knock-down of hBCATm with 3 different synthesised siRNAs.....	213

Figure 4.5 – Validation of siRNA duplexes.....	214
Figure 4.6 – Agarose gel analysis of qPCR primer products.....	216
Figure 4.7 – Relative quantification of BCAT1 and BCAT2 mRNA.	217
Figure 4.8 – Melt curve analysis of qPCR products.	218
Figure 4.9 – Expression of hBCATm in transfected and L-leucine treated SH-SY5Y neuronal cells.	220
Figure 4.10 – Expression of PDI in transfected and L-leucine treated SH-SY5Y neuronal cells.	222
Figure 4.11 – Expression of GRx-1 in transfected and L-leucine treated SH-SY5Y neuronal cells.	214
Figure 4.12 – Expression of TRx-1 in transfected and L-leucine treated SH-SY5Y neuronal cells.	225
Figure 4.13 – Expression of BCKDHA in transfected and L-leucine treated SH-SY5Y neuronal cells.	227
Figure 4.14 – Expression of AUH in transfected and L-leucine treated SH-SY5Y neuronal cells.	228
Figure 4.15 – Expression of hBCATm in transfected and L-glutamate treated SH-SY5Y neuronal cells.	230
Figure 4.16 – Expression of GDH in transfected and L-glutamate treated SH-SY5Y neuronal cells.	231
Figure 4.17 – Rate of TNB²⁻ formation at set concentrations of GSH treated with DTNB.	233
Figure 4.18 – Rate of TNB²⁻ formation proportional to total glutathione concentration in prepared SH-SY5Y lysates.....	234
Figure 4.19 – Concentration of total glutathione in transfected SH-SY5Y cells.	235
Figure 4.20 – Rate of TNB²⁻ formation proportional to oxidised glutathione concentration in prepared SH-SY5Y lysates.....	236
Figure 4.21 – Concentration of oxidised glutathione in transfected SH-SY5Y cells.	237
Figure 4.22 – Concentration of reduced glutathione in transfected SH-SY5Y cells.	239

<i>Figure 4.23</i> – Ratio of reduced to oxidised glutathione in transfected SH-SY5Y cells.	240
<i>Figure 4.24</i> – Metabolic activity of transfected SH-SY5Y cells determined by MTS reduction.	242
<i>Figure 4.25</i> – Pathways for hBCATm and L-leucine metabolism in ARE activation.	248
<i>Figure 4.26</i> – Radiolabelled substrate tracer studies.	252
<i>Figure 4.27</i> – The metabolism of L-leucine and involvement accumulation of 3-methylglutaconic acid.	254
<i>Figure 4.28</i> – A model of the hBCATm-GDH metabolon for increased glutathione and energy production.	257

CHAPTER FIVE – IN VITRO MODELING OF THE HUMAN BLOOD-BRAIN BARRIER.

<i>Figure 5.1</i> – Representation of a culture well insert and the contributing cells... ..	262
<i>Figure 5.2</i> – Tetracycline inducible transcription of shRNA.	265
<i>Figure 5.3</i> – Permeability of hCMEC/D3 monolayers over time.	269
<i>Figure 5.4</i> – Expression of tight junction proteins in hCMEC/D3 cells.	271
<i>Figure 5.5</i> – First transfections of hCMEC/D3 cells.	272
<i>Figure 5.6</i> – Transfection of eGFP plasmid in hCMEC/D3 and SH-SY5Y cells. ..	274
<i>Figure 5.7</i> – Timed hBCATm plasmid transfection.	275
<i>Figure 5.8</i> – Titration of siRNA concentration with jetPRIME reagent.	276
<i>Figure 5.9</i> – Transfection of cells with a fluorescently labelled siRNA.	277
<i>Figure 5.10</i> – Knock-down of hBCATm in SH-SY5Y and hCMEC/D3 cells using RNAiMAX transfection reagent.	279
<i>Figure 5.11</i> – Digestion of pLKO plasmid.	281
<i>Figure 5.12</i> – The BCAT2 shRNA sequence design.	282
<i>Figure 5.13</i> – Partial sequence of pLKO-BCAT2 plasmid.	283
<i>Figure 5.14</i> – Digestion of pLKO-BCAT plasmids.	284

CHAPTER SIX – SYNOPSIS, CONCLUSION, AND FUTURE WORK.

<i>Figure 6.1 – A new proposed hBCAT-glutamate-glutamine cycle incorporating GDH...</i>	292
<i>Figure 6.2 – Vascular stress in AD pathogenesis.....</i>	295

TABLE CONTENTS.

CHAPTER ONE – INTRODUCTION AND MAIN AIMS.

Table 1.1 – hBCAT isoform transamination..	7
--	---

CHAPTER TWO – MATERIALS AND METHODS.

Table 2.1 – Materials and manufacturer	48
Table 2.2 – Primer sequences.....	55
Table 2.3 – Antibody list.....	56
Table 2.4 – Parameters for usage of NMR spectroscopy.....	62
Table 2.5 – Concentrations of inhibitors analysed using the radioactive method.	70
Table 2.6 – Quantity of material for siRNA and plasmid transfection.....	78

CHAPTER THREE – CHEMICAL SYNTHESIS AND ANALYSIS OF A SELECTIVE HBCATM INHIBITOR.

Table 3.1 – The total protein concentration of each purified hBCAT isoform as determined by the Bradford protein estimation assay.....	98
Table 3.2 – The kinetic activity of each purified hBCAT isoform.....	105
Table 3.3 – The effect of gabapentin on hBCAT activity.....	111
Table 3.4 – The effect of dipropylglycine on hBCAT activity.....	114

Table 3.5 – The Glide XP scores of a selection of compounds docked with hBCATm during lead compound optimisation. 117

Table 3.6 – NMR peaks of BOPAA derivative inhibitors..... 161

Table 3.7 – Summary of candidate hBCAT inhibitors assayed in this study..... 183

CHAPTER FOUR – THE ROLE OF HBCATM IN REDOX STATUS AND METABOLISM.

Table 4.1 – Summary of findings into the impact of hBCATm on neuronal cell protein expression, glutathione levels, and cell metabolic activity 244